SPONSOR
Fujian Cancer Hospital
Total Trials
8
Recruiting
8
Phases
Phase 3, Phase 2
Conditions studied: Breast Neoplasm FemaleTriple -Negative Breast CancerGastric CancerBreast CancerHR+/HER2- Breast CancerBreast NeoplasmsBreast DiseasesDalpiciclibEndocrine Breast DiseasesCDK4/6 Inhibitor
Fujian Cancer Hospital is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Breast Neoplasm Female, Triple -Negative Breast Cancer, Gastric Cancer, Breast Cancer.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fujian Cancer Hospital
How many clinical trials has Fujian Cancer Hospital sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Fujian Cancer Hospital, of which 8 are actively recruiting participants. These trials cover conditions including Breast Neoplasm Female, Triple -Negative Breast Cancer, Gastric Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fujian Cancer Hospital research focus on?
Fujian Cancer Hospital clinical trials span Breast Neoplasm Female, Triple -Negative Breast Cancer, Gastric Cancer, Breast Cancer, HR+/HER2- Breast Cancer, and additional conditions. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fujian Cancer Hospital clinical trial?
To participate in a Fujian Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fujian Cancer Hospital trials with current recruitment status updated daily.
Clinical Trials by Fujian Cancer Hospital
NCT07880600
Recruiting
Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
Breast Neoplasm Female
NCT06793917 Phase 3
Recruiting
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
NCT07467330 Phase 3
Recruiting
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Breast Cancer
NCT07702708
Recruiting
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
HR+/HER2- Breast Cancer
NCT07581834 Phase 2
Recruiting
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Breast Diseases
NCT07142122
Recruiting
Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
Gastric Cancer
NCT07469306 Phase 2
Recruiting
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
NCT07256236 Phase 2
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology